Exploring a Kinetic Model Approach in Biopharmaceutics: Estimating the Fraction Absorbed of Orally Administered Drugs in Humans

被引:11
作者
Chiang, Po-Chang [1 ]
Liu, Jia [1 ]
Fan, Peter [2 ]
Wong, Harvey [3 ]
机构
[1] Genentech Inc, Global Res & Dev, SMPS, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA
[3] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
关键词
fraction absorbed; pharmacokinetics; PBPK; absorption; absorption efficiency; % Fa; modeling; INTESTINAL PERMEABILITY; MEMBRANE-PERMEABILITY; CACO-2; CELLS; ABSORPTION; PREDICTION; CLASSIFICATION; BIOAVAILABILITY; BENOXAPROFEN; DISCOVERY; DISSOLUTION;
D O I
10.1016/j.xphs.2018.03.015
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Increasing costs of research and development in the pharmaceutical industry has necessitated a growing interest in the early prediction of human pharmacokinetics of drug candidates. Of growing interest is the need to understand oral absorption, the most common route of small molecule drug administration. The fraction of dose absorbed (%Fa) is considered a critical yet challenging parameter to predict. A kinetic model has been developed and tested to provide an early prediction of the fraction dose absorbed in humans. Unlike the traditional plug-flow model, this model assumes first-order kinetics to estimate the amount of drug present in the stomach and small intestine as a function of time and calculates the amount of drug released and absorbed during the transit. Other variables can be included in calculation as a function of time to better mimic the physiological condition with this approach. Absorption efficiency is assigned along with %Fa to give a quantitative estimate of the limiting factor for oral absorption. The model was tested with literature and in-house compounds. It was found that this model gives a good prediction of human %Fa with a correction coefficient (R-2) of 0.8 and greater between predicted and reported %Fa for all compounds. (C) 2018 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1798 / 1805
页数:8
相关论文
共 47 条
  • [11] The Fraction Dose Absorbed, in Humans, and High Jejunal Human Permeability Relationship
    Dahan, Arik
    Lennernas, Hans
    Amidon, Gordon L.
    [J]. MOLECULAR PHARMACEUTICS, 2012, 9 (06) : 1847 - 1851
  • [12] DAVENPORT H.W., 1982, Physiology of the Digestive Tract
  • [13] ABSORPTION POTENTIAL - ESTIMATING THE FRACTION ABSORBED FOR ORALLY-ADMINISTERED COMPOUNDS
    DRESSMAN, JB
    AMIDON, GL
    FLEISHER, D
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1985, 74 (05) : 588 - 589
  • [14] Predicting Phenolic Acid Absorption in Caco-2 Cells: A Theoretical Permeability Model and Mechanistic Study
    Farrell, Tracy L.
    Poquet, Laure
    Dew, Tristan P.
    Barber, Stuart
    Williamson, Gary
    [J]. DRUG METABOLISM AND DISPOSITION, 2012, 40 (02) : 397 - 406
  • [15] Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data
    Gertz, Michael
    Harrison, Anthony
    Houston, J. Brian
    Galetin, Aleksandra
    [J]. DRUG METABOLISM AND DISPOSITION, 2010, 38 (07) : 1147 - 1158
  • [16] Selamectin is a potent substrate and inhibitor of human and canine P-glycoprotein
    Griffin, J
    Fletcher, N
    Clemence, R
    Blanchflower, S
    Brayden, DJ
    [J]. JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 2005, 28 (03) : 257 - 265
  • [17] MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening
    Irvine, JD
    Takahashi, L
    Lockhart, K
    Cheong, J
    Tolan, JW
    Selick, HE
    Grove, JR
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1999, 88 (01) : 28 - 33
  • [18] A novel strategy for physiologically based predictions of human pharmacokinetics
    Jones, HM
    Parrott, N
    Jorga, K
    Lavé, T
    [J]. CLINICAL PHARMACOKINETICS, 2006, 45 (05) : 511 - 542
  • [19] COMPARISON OF THE GASTROINTESTINAL ANATOMY, PHYSIOLOGY, AND BIOCHEMISTRY OF HUMANS AND COMMONLY USED LABORATORY-ANIMALS
    KARARLI, TT
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 1995, 16 (05) : 351 - 380
  • [20] Molecular properties of WHO essential drugs and provisional biopharmaceutical classification
    Kasim, Nehal A.
    Whitehouse, Marc
    Ramachandran, Chandrasekharan
    Bermejo, Marival
    Lennernas, Hans
    Hussain, Ajaz S.
    Junginger, Hans E.
    Stavchansky, Salomon A.
    Midha, Kamal K.
    Shah, Vinod P.
    Amidon, Gordon L.
    [J]. MOLECULAR PHARMACEUTICS, 2004, 1 (01) : 85 - 96